Why Daily Baby Moisturizer Did Not Prevent Eczema in Large Trials

Daily whole-body moisturizer from birth does not stop babies from developing eczema. Two large, carefully run randomized trials set out to prove that it would, and both landed on the same disappointing answer: no reduction in atopic dermatitis, plus early hints that the moisturized infants caught more skin infections. It is one of the cleaner recent examples of a hypothesis that made almost perfect sense on paper and still failed the only test that counts.

Key points#

• Two large trials, BEEP in the UK and PreventADALL in Scandinavia, tested daily infant emollient as eczema prevention. Neither worked at its main endpoint.
• BEEP found more skin infections in the moisturized group. A 2022 Cochrane review pooled the wider evidence and reached the same conclusion.
• The idea rested on a real and well-supported biology (a leaky skin barrier), which is exactly why the negative result is instructive.
• Guidelines no longer recommend moisturizer to prevent eczema, even in high-risk babies. Gentle skin care for comfort is still fine.

The biology that made the idea irresistible#

To see why anyone ran these trials, start with what goes wrong in eczema. Atopic dermatitis usually shows up in the first months of life, and one of its earliest fingerprints is a skin barrier that leaks. The outer layer of skin is meant to work like grout between tiles, sealing water in and keeping irritants and allergens out. In many children with eczema that seal is faulty. The clearest evidence comes from the filaggrin gene, which helps build the barrier: children who inherit loss-of-function variants carry a markedly higher risk of eczema.

From there, a tidy chain of reasoning takes shape. A weak barrier lets water escape and lets allergens slip in through the skin. Early skin sensitization could then feed the "atopic march," the tendency for infant eczema to be followed by food allergy and later asthma. If all of that traces back to a barrier problem present from birth, then patching the barrier early, with nothing more exotic than moisturizer, might interrupt the whole sequence. Few prevention ideas in pediatrics have looked this mechanistically clean.

Encouraging pilots, then the real test#

The idea was not pulled from thin air. Two small pilot trials published in 2014, one run across the US and UK and one in Japan, each enrolled roughly 120 high-risk newborns and reported that daily emollient cut early eczema by about half. Those are eye-catching numbers, and they did exactly what good pilot data should do: justify the cost and effort of large confirmatory trials. This is the evidence pipeline working as intended, moving from mechanism to a small signal to a properly powered test.

Two such tests followed. BEEP randomized 1,394 UK newborns who had a family history of atopic disease to either daily whole-body emollient for the first year plus standard skin-care advice, or the standard advice alone. Its primary outcome was clinically assessed eczema at age two. PreventADALL took a broader, general-population sample of 2,397 infants in a factorial design, assigning a skin regimen (emollient bath additives plus facial cream, used at least four days a week from two weeks of age) with or without early introduction of allergenic foods. Its primary outcome was atopic dermatitis by twelve months.

What the large trials found#

The effect on eczema was essentially flat. In BEEP, eczema was present in 23 percent of the emollient group versus 25 percent of controls, an adjusted relative risk of 0.95 (95% CI 0.78 to 1.16). In PreventADALL, atopic dermatitis occurred in 11 percent of the skin-intervention group versus 8 percent of the no-intervention group, a difference that, if anything, tilted slightly toward the control side. Longer follow-up did not rescue the idea either: the BEEP five-year results, reported in 2023, found no protection against eczema, food allergy, asthma, or hay fever through age five.

The safety picture is what turns a disappointing result into a discouraging one. A neutral efficacy finding is merely unhelpful; a neutral finding paired with a hint of harm actively argues against the strategy. In BEEP, infants in the emollient group averaged more skin infections during the first year (adjusted incidence rate ratio 1.55, 95% CI 1.15 to 2.09). The 2022 Cochrane systematic review, pooling data across dozens of trials, sharpened the same verdict: infant skin-care interventions probably do not change eczema risk (risk ratio 1.03, 95% CI 0.81 to 1.31), probably raise skin infections (risk ratio 1.33, 95% CI 1.01 to 1.75), and may raise the risk of IgE-mediated food allergy. Notably, the benefit did not appear even in babies carrying filaggrin mutations, the exact subgroup the mechanism said should gain the most. PreventADALL did not report the same rise in skin infections, so the infection signal is not uniform across every protocol, but the "no prevention" conclusion is.

How to read a reversal like this#

A result this clean is worth keeping as a teaching case, because the same reasoning traps show up across medicine. Three points travel well beyond eczema, and you will meet all three again.

First, an impressive signal in a small trial often melts toward zero once a study is large enough to measure it honestly. Regression toward the null is closer to the rule than the exception, which is why a halving of risk in 120 infants did not survive in 1,394.

Second, moving a measurable surrogate is not the same as moving the outcome you actually care about. Moisturizer can genuinely improve skin hydration and barrier function on a monitor, and still leave the rate of diagnosed eczema untouched. The surrogate improved; the diagnosis did not follow.

Third, prevention has to clear a higher bar than treatment. A preventive routine is applied to healthy children who were never going to develop the disease, so any harm, even something as ordinary as extra skin infections, weighs heavily against a benefit that turned out not to exist. That is the sum to do before you start any routine on a well child.

The trial teams and later guideline reviews reached the practical conclusion together: daily emollient should not be recommended to prevent eczema in newborns, high atopic risk or not. Everyday gentle skin care to keep your baby comfortable remains perfectly reasonable. Using moisturizer as though it were a preventive drug is what does not hold up.